---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-000144"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T18:08:12.990587+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics loses foreign private issuer status, will file as U.S. domestic issuer from Jan 1, 2025

## Summary
- Effective January 1, 2025, Silence Therapeutics (SLN) will file periodic reports on U.S. domestic issuer forms, no longer as a foreign private issuer.
- Domestic issuer filings are more detailed and extensive, and must be filed more promptly than foreign private issuer forms.
- Company announced it will disseminate material information via press releases, its website, investor relations page, LinkedIn, and X account.
- No other material business or financial updates were included in the filing.

## SEC filing metadata
- accession: 0001193125-25-000144
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525000144/0001193125-25-000144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525000144/d921843d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-000144
- JSON: https://secwatch.observer/filing/0001193125-25-000144.json
- Plain text: https://secwatch.observer/filing/0001193125-25-000144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.